Down State Medical F18 FDG review cancelled
Executive Summary
A Nov. 19 review of Down State Medical's positron emission tomography agent F18 fluoro-D-glucose (FDG) for the diagnosis and/or identification of Alzheimer's disease progression has been cancelled. FDA's Peripheral & Central Nervous System Drugs Committee still will discuss the use of Alzheimer's brain imaging as a surrogate endpoint in clinical trials on Nov. 18 (1"The Pink Sheet" Sept. 30, In Brief)...
You may also be interested in...
Alzheimer’s and brain imaging
The role of brain imaging as an outcome measure in Phase III Alzheimer's Disease trials will be discussed at a joint meeting of FDA's Peripheral & Central Nervous System Drugs and Medical Imaging Drugs Advisory Committees Nov. 18. On Nov. 19, the committees will review Down State Medical's positron emission tomography agent F18 fluoro-D-glucose for imaging in Alzheimer's Disease. The meeting will take place at the Holiday Inn, Gaithersburg, Md...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.